Contact    |    Site Map    |    Careers



Lymphoma Clinical Trials

Acetylon’s collaborators at Columbia University Medical Center are currently conducting an investigator-sponsored study of ricolinostat (ACY-1215) as monotherapy for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphoma.

A Phase 1b/2, Open-label, Multicenter Study of the Selective HDAC6 Inhibitor, Ricolinostat, for the Treatment of Patients with Relapsed or Refractory Lymphoid Malignancies

The multicenter study is being conducted to evaluate the safety and efficacy of ricolinostat as monotherapy in the treatment of lymphomas. This study is enrolling patients with both Hodgkin and non-Hodgkin lymphomas. For more information, including trial locations, please refer to clinicaltrials.gov study NCT 02091063.